Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is it reasonable to use hypofractionation in breast cancer patients with non-active connective tissue disorders?
Answer from: Radiation Oncologist at Academic Institution
Yes, it is reasonable to use hypofractionation in this patient panel. I have used the Canadian fractionation schedule several times in this scenario.
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
I’ve also routinely done this with no issue at all.
Sign In
or
Register
to read more
15771
15793
Related Questions
Does micropapillary subtype for a G1-2 DCIS affect your radiation treatment recommendations?
Is re-excision of residual disease ever itself an indication for PMRT?
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
In what circumstances would you offer axillary re-irradiation after salvage axillary dissection?
In what patients is it inappropriate to offer DCISionRT testing?
In a young woman with large invasive breast carcinoma (case: pT3, lobular) s/p skin sparing mastectomy with positive anterior margin, what is the practical role for re-excision with or without PMRT?
How do you optimally set a patient up for breast radiation therapy if you don't have access to a breast board or wing board?
Is there additional concern for late cardiac toxicity when using ultrahypofractionated breast radiation protocols, given that the BED to the heart is higher?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?